Regulation of Glucose Control in People with Type 2 Diabetes: A Review and Consensus

다국어 초록 (Multilingual Abstract)

A conference was convened by the Korean Diabetes Association and the Korean Endocrine Society on September 7, 2009 to discuss and organize the results of research on intensive glucose control for the prevention of cardiovascular disease in patients with type 2 diabetes. Professor Kyung Soo Park led the conference, and Professors Kwang Won Kim and Ho Young Son acted as chairmen.
Professors Doo Man Kim, Tae Sun Park, and Bong Soo Cha reported on intensive glucose control and diabetic complications,including the UKPDS, DCCT research results, the recently published ACCORD, ADVANCE, and VADT research, as well as meta-analyses. Professor Jeong-taek Woo reported on the manuscript written by the committee for the Korean Diabetes Association which dealt with the treatment of diabetes mellitus. Professors Kyung Soo Ko, Joong Yeol Park, Hyun Shik Son, Moon-Kyu Lee, Dong-Won Byun, and Yoon-Sok Chung participated in the discussion and collected information for the manuscript from all of the participants. The aim of the debate was to determine how to establish target goals for intensive glucose control and how to individualize those goals. The participants concluded that there was no need to modify the recommendation of maintaining an HbA1c under 6.5%, the current blood glucose treatment goal that is recommended by the Korean Diabetes Association.
In addition, individual target goals for glucose control were recommended depending on the situation of each patient. We report on the consensus statement from the meeting.

참고문헌 (Reference)

1 Duckworth W, "VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes" 360 : 129-139, 2009

2 ONTARGET Investigators, "Telmisartan, ramipril, or both in patients at high risk for vascular events" 358 : 1547-1559, 2008

3 American Diabetes Association, "Standards of medical care in diabetes - 2009" 32 (32): 13-61, 2009

4 Dormandy JA, "PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial" 366 : 1279-1289, 2005

5 Holman RR, "Longterm follow-up after tight control of blood pressure in type 2 diabetes" 359 : 1565-1576, 2008

6 hkubo Y, "Intensive insulin thera py prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study" 28 : 103-117, 1995

7 UK Prospective Diabetes Study (UKPDS) Group, "Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes" 352 : 837-853, 1998

8 ADVANCE Collaborative Group, "Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes" 358 : 2560-2572, 2008

9 Barter PJ, "ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events" 357 : 2109-2122, 2007

10 Action to Control Cardiovascular Risk 555 in Diabetes Study Group, "Effects of intensive glucose lowering in type 2 diabetes" 358 : 2545-2559, 2008

11 Ray KK, "Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials" 373 : 1765-1772, 2009

12 Kastelein JJ, "ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia" 358 : 1431-1443, 2008

13 Korean Diabetes Association, "Clinical practice guideline" MM Communications 40-42, 2007

14 Holman RR, "10- year follow-up of intensive glucose control in type 2 diabetes" 359 : 1577-1589, 2008